AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 12, 2025, discloses material definitive agreements entered into by AEON Biopharma, Inc. (AEON). The filing details a private placement of equity securities and a proposed exchange of outstanding senior secured convertible notes held by Daewoong Pharmaceutical Co., Ltd. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Terms
The filing outlines the following financial terms for the proposed transactions:
- Private Placement Price: $0.9116 per share of Class A Common Stock (or $0.9115 per Pre-Funded Warrant).
- First Closing (Expected Week of Nov 17, 2025): Issuance of approximately 1,964,905 Shares or Pre-Funded Warrants.
- Second Closing (Subject to Conditions): Issuance of approximately 4,616,924 Shares or Pre-Funded Warrants and 6,581,829 Warrants.
- Warrant Exercise Price: $1.09392 per share for standard Warrants and Daewoong Warrants.
- Convertible Note Exchange: Existing notes to be exchanged for a new $1.5 million senior secured convertible note due 2030, approximately 23,103,694 Exchange Shares (estimated), and 8 million Daewoong Warrants.
- Antidilution Protection: Warrants include full ratchet antidilution protection with a floor exercise price of $0.30387 per share.
The filing does not provide current revenue, profit, cash flow, or total debt figures; it focuses exclusively on the terms of the new financing and debt restructuring.
Material Changes and Conditions
The proposed transactions represent a significant change in the Company's capital structure and debt obligations. Key conditions precedent include:
- Stockholder Approval: Required for the Second Closing of the Private Placement and the consummation of the Daewoong Exchange under NYSE American rules.
- True-Up Warrants: Investors will receive additional warrants to maintain their pro-rata ownership percentage following the issuance of Exchange Shares to Daewoong.
- Registration Rights: The Company must file a registration statement for the resale of securities within 20 days of the earlier of the Second Closing or termination of the agreement.
Outlook, Risks, and Contingencies
Management expects the First Closing to occur the week of November 17, 2025. The Second Closing and the Daewoong Exchange are contingent upon stockholder approval and other customary conditions. The filing includes standard forward-looking statements regarding the ability to consummate these transactions.
Key Risks:
- Failure to obtain necessary stockholder approval.
- Failure to satisfy closing conditions for the Private Placement or Exchange.
- Dilution to existing shareholders due to the issuance of shares, warrants, and the exchange of debt for equity.
Investor Verification Checklist
- Verify the outcome of the stockholder vote required for the Second Closing and the Daewoong Exchange.
- Confirm the exact number of Exchange Shares issued to Daewoong once the final principal and accrued interest on existing notes are calculated.
- Review the upcoming Proxy Statement (Schedule 14A) for detailed terms of the solicitation and voting procedures.
- Monitor the filing of the registration statement for the resale of the new securities within the 20-day deadline.
- Assess the impact of the full ratchet antidilution provision on future financing rounds.